<DOC>
	<DOCNO>NCT00005615</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . Combining interferon alfa plus radiation therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness interferon alfa plus radiation therapy treat patient stage III recurrent melanoma remove surgery .</brief_summary>
	<brief_title>Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effectiveness toxicity adjuvant radiotherapy give concurrently interferon alfa patient stage III recurrent melanoma . OUTLINE : This multicenter study . Patients receive interferon alfa IV 20 minute daily 5 consecutive day week 4 week . Patients receive radiotherapy day 2 4 interferon alfa subcutaneously ( SQ ) day 1 , 3 , 5 2.5 week . Interferon alfa SQ continue 3 time week 10 month absence disease progression unacceptable toxicity . Patients follow every month 3 month , every 3 month 2 year , every six month year 5 , annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study within 2.75 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven primary melanoma extensive regional node metastasis ( T14 , N1 , M0 ) OR Primary melanoma clinically apparent metastasis confirm lymphadenectomy ( T14 , N12 , M0 ) OR Clinically detect relapse melanoma regional node basin , confirm lymphadenectomy prior management primary site ( T14 , N12 , M0 ) OR Recurrence melanoma nodal basin previously resect OR Nodal metastatic melanoma arise unknown primary , confirmed lymphadenectomy ( Tx , N12 , M0 ) Adenopathy neck , axilla , groin basin must meet one follow criterion : At least 4 positive node contain tumor Nodal metastases least 3 cm size Gross extracapsular extension tumor Recurrence prior lymphadenectomy Completely resect disease No distant metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : At least 6 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 125,000/mm3 Hematocrit least 33 % Hepatic : AST , LDH , alkaline phosphatase bilirubin great 2 time upper limit normal Renal : Creatinine great 1.8 mg/dL BUN great 33 mg/dL Cardiovascular : No congestive heart failure ( New York Heart Association class III IV heart disease ) Neurologic : No prior CNS demyelinate inflammatory disease No prior hereditary acquire peripheral neuropathy No organic brain syndrome , significant impairment cognitive function , psychiatric disorder would preclude study Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 18 month study No hypersensitivity interferon alfa component injection No history diabetes mellitus prone ketoacidosis No uncontrolled thyroid abnormalities No clinically significant retinal abnormality No significant medical surgical condition would preclude study No prior invasive melanoma No prior concurrent malignancy within past 5 year except situ cancer , atypical melanocytic hyperplasia , basal squamous skin cancer No autoimmune disorder immunosuppressive condition PRIOR CONCURRENT THERAPY : Biologic therapy : Prior vaccine therapy allow No prior immunotherapy , interferon , interleukin , levamisole , biologic response modifier Chemotherapy : No prior chemotherapy , include infusion perfusion therapy Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : No prior radiotherapy propose site ( ) study Surgery : See Disease Characteristics Other : No medication treatment regimen would preclude study No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>